Alzheimer's trials
An Alzheimer's disease prevention trial has picked three experimental drugs that it will test from 2013. The Dominantly Inherited Alzheimer's Network Therapeutic Trials Unit at Washington University
Better biomarkers
The US National Cancer Institute has released draft guidelines meant to prevent the sloppy use of biomarkers in clinical trials. Chief among the new rules are precautions against imposing signals on noise, as biologists comb through massive data sets
POLICY

Genome privacy
Researchers and funding bodies should protect people's privacy even as they hope to use data from genome sequencing to improve medical treatments, a US government ethics panel said on 11 October. The report from the Presidential Commission for the Study of Bioethical Issues called for consistent policies to protect individuals' data, including making it illegal to sequence people without their knowledge or consent. See go.nature. com/1g744j for more.
RESEARCH
ORCID launch
A registry that will grant scientists a unique identifying number -helping readers of the literature to distinguish between authors with similar names -launched on 16 October. ORCID, the Open Researcher and Contributor ID, is supported by funds and input from member institutions, publishers (including Nature Publishing Group) and scientific societies. It should integrate with existing researcher identification systems and make it easier for universities and funding agencies to track scientists' output (see Nature 485, 564; 2012). Researchers can register at www.orcid.org and add information about their publications to their ORCID records.
EVENTS
Space commerce
The Dragon spacecraft carried 400 kilograms of cargo to the International Space Station on 10 October -marking the first journey in a 12-flight, US$1.6-billion contract between NASA and commercial firm SpaceX, in Hawthorne, California. Another company, Orbital Sciences of Dulles, Virginia, will also attempt commercial resupply of the station; it is set to test-fly its Antares rocket and Cygnus capsule later this year.
Texas tribulations
All the members of the scientific review council of the Cancer Prevention and School of Medicine in St Louis, Missouri, said on 10 October that it would test drugs from Roche and Eli Lilly in people with rare mutations that can go on to cause Alzheimer's. One of the drugs, solanezumab, failed clinical trials in August (see Nature 489, 13-14; 2012) . But independent sub-analyses, released on 8 October at a meeting of the American Neurological Association in Boston, Massachusetts, to find markers that may be linked to disease. Patterns found in large-scale genomic or proteomic data must be re-evaluated using an independent data set, noted the guidelines, published on 11 October. The move comes after clinical trials in cancer were halted for problems including erroneous data (see Nature 469, 139-140; 2011) . See go.nature.com/zzuqdg for more.
suggested that the drug did slow cognitive decline in some people with mild forms of Alzheimer's. 
TREND WATCH
The springtime destruction of ozone over Antarctica reached its annual maximum in early October, with the ozone hole slightly less wide, and its minimum ozone concentration slightly higher, than in previous seasons (see chart). The Montreal Protocol, signed 25 years ago, seems to have led to decreasing atmospheric levels of the chlorine and bromine chemicals that destroy ozone. But NASA's Paul Newman estimates that chlorine and bromine will not return to their 1980 levels until about 2065.
ANTARCTIC OZONE RECOVERING
The ozone hole over Antarctica is slowly shrinking back to pre-1980 levels. 
PEOPLE
Dolly cloner dies
Keith Campbell (pictured), the reproductive biologist who helped to clone Dolly the sheep from a mammary-gland 
Stem-cell lawsuit
